Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 02, 2023 16:30 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

SEATTLE, May 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that six...
April 24, 2023 16:05 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology to Host Research & Development Day

SEATTLE, April 24, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that management...
April 19, 2023 16:05 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting

Hypoimmune-modified CD19-directed CAR T cells persist and remain functional in preclinical models over multiple months in an allogeneic humanized immune system, even with tumor re-challenge SC291...
April 13, 2023 09:00 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses

Hypoimmune-modified allogeneic CD19-directed CAR T cells can evade immune detection and kill tumor cells in a novel humanized allogeneic preclinical model in vivo, including following tumor cell...
April 12, 2023 16:05 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model

Hypoimmune human islet cells normalized glucose in diabetic humanized immunocompetent mouse model and avoided allogeneic and autoimmune rejection by the immune system Similar hypoimmune primary human...
April 10, 2023 16:05 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization

Dr. Douglas E. Williams as Head of Research and Development Dr. Gary Meininger as Chief Medical Officer SEATTLE, April 10, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a...
March 16, 2023 16:05 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Announced SC291 IND clearance with goal to report initial clinical data this year Expect to initiate investigator-sponsored trial with hypoimmune-modified primary islet cells with potential...
March 14, 2023 16:53 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting

SEATTLE, March 14, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that four abstracts,...
March 01, 2023 16:05 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference

SEATTLE, March 01, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
February 02, 2023 16:05 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference

SEATTLE, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...